结直肠癌肝转移患者血清miR-618水平及意义  

Levels and significance of miR-618 in liver metastasis of colorectal cancer

作　　者：傅冬梅 刘莉 朱杰伦 FU Dongmei;LIU Li;ZHU Jielun(Department of Gastroenterology,General Hospital of Central Theater Command,Wuhan,Hubei 430012,China)

机构地区：[1]中部战区总医院消化内科,湖北武汉430012

出　　处：《检验医学与临床》2024年第16期2315-2319,共5页Laboratory Medicine and Clinic

基　　金：2022年湖北省自然科学基金:立项项目(2022CFC062)。

摘　　要：目的探讨血清微小RNA(miR)-618在结直肠癌肝转移患者中的水平及意义。方法选取2016年1月至2019年1月该院收治的188例结直肠癌患者作为研究对象,根据是否发生肝转移分为转移组(58例)和未转移组(130例)。比较两组术前血清miR-618水平及不同临床病理特征肝转移患者血清miR-618水平,并绘制受试者工作特征(ROC)曲线分析血清miR-618在诊断结直肠癌患者发生肝转移中的临床价值。转移组随访3年,根据随访结果分为预后良好组和预后不良组,比较两组血清miR-618水平,并绘制ROC曲线分析血清miR-618预测结直肠癌肝转移患者预后的临床价值。结果转移组与未转移组患者的肿瘤分化程度、浸润深度及淋巴结分期比较,差异均有统计学意义(P<0.05)。转移组血清miR-618水平为0.70±0.20,明显低于未转移组的1.03±0.40,差异有统计学意义(t=5.803,P<0.001)。中/高分化患者的血清miR-618水平高于低分化患者(P<0.05);肿瘤浸润深度为T3和T4期患者的血清miR-618水平低于T1/T2期,且T4期患者的血清miR-618水平低于T3期患者,差异均有统计学意义(P<0.05);淋巴结分期为N1和N2期患者的血清miR-618水平低于N0期患者,且N2期患者血清miR-618水平低于N1期患者,差异均有统计学意义(P<0.05)。ROC曲线分析结果显示,血清miR-618截断值为0.787时,其诊断结直肠癌患者发生肝转移的曲线下面积(AUC)为0.883。随访3年,58例肝转移患者中有25例纳入预后不良组,其余33例纳入预后良好组。预后不良组的血清miR-618水平为0.64±0.20,明显低于预后良好组的0.75±0.19,差异有统计学意义(t=2.270,P=0.027)。ROC曲线结果显示,当血清miR-618最佳截断值为0.678时,其诊断结直肠癌肝转移患者预后不良的AUC为0.701。结论结直肠癌肝转移患者血清miR-618水平与病情程度密切相关,且血清miR-618水平可辅助诊断肝转移患者预后。Objective To investigate the expression level of miR-618 in patients with colorectal cancer liver metastasis and its clinical significance.Methods A total of 188 patients with colorectal cancer admitted to the hospital from January 2016 to January 2019 were selected as the study objects,which were divided into metastasis group(58 cases)and non-metastasis group(130 cases)according to the occurrence of liver metastasis.The preoperative serum miR-618 levels between the two groups and the serum miR-618 levels of liver metastasis patients with different clinical characteristics were compared,and the clinical value of serum miR-618 in diagnosing the occurrence of liver metastasis in colorectal cancer patients was analyzed by plotting receiver operating characteristic(ROC)curve.The metastasis group was followed up for 3 years and divided into good prognosis group and poor prognosis group according to the prognosis,serum miR-618 levels were compared between the two groups,and ROC curves were plotted to analyze the clinical value of serum miR-618 in predicting the prognosis of patients with liver metastasis.Results Comparison of tumor differentiation degree,infiltration depth and lymph node staging between the metastasis group and the non-metastasis group showed statistically significant differences(P<0.05).The serum miR-618 level in the metastasis group was 0.70±0.20,which was significantly lower than 1.03±0.40 in the non-metastasis group,and the difference was statistically significant(t=5.803,P<0.001).The serum miR-618 level in moderately/highly differentiated patients was higher than that in poorly differentiated patients(P<0.05);the serum miR-618 levels in patients with tumor infiltration depths of stages T3 and T4 were lower than those of stages T1/T2,and serum miR-618 level of stage T4 was lower than that of stage T3,with statistically significant differences(P<0.05);the serum miR-618 levels of patients with lymph node staging of stages N1 and N2 were lower than those of stage N0,and serum the miR-618 level of st

关 键 词：微小RNA-618 结直肠癌 肝转移 分化程度 淋巴结分期 预后 

分 类 号：R735.34[医药卫生—肿瘤]